MAZE THERAPEUTICS, INC. COMMON STOCK
NASDAQ: MAZE (Maze Therapeutics, Inc.)
最近更新时间: 6小时之前31.37
-1.06 (-3.27%)
| 前收盘价格 | 32.43 |
| 成交量 | 818,930 |
| 平均成交量 (3个月) | 737,145 |
| 市值 | 1,715,416,576 |
| 价格/销量 (P/S) | 89.15 |
| 股市价格/股市净资产 (P/B) | 4.13 |
| 52周波幅 | |
| 利润日期 | 9 Nov 2026 |
| 营业利益率 (TTM) | -820.82% |
| 稀释每股收益 (EPS TTM) | -2.62 |
| 总债务/股东权益 (D/E MRQ) | 13.92% |
| 流动比率 (MRQ) | 14.14 |
| 营业现金流 (OCF TTM) | -114.74 M |
| 杠杆自由现金流 (LFCF TTM) | -68.62 M |
| 资产报酬率 (ROA TTM) | -21.98% |
| 股东权益报酬率 (ROE TTM) | -37.49% |
AIStockmoo 评分
| 价值 30% | 0.0 |
| 负债低。盈利能力弱。短期流动性充足。现金流为负。 参考 | |
| 来自我们的 AI Insight 报告对预期回报与风险的评估。 参考 | NA |
| 相对估值 参考 | NA |
| 隐含增长 参考 | NA |
| 历史估值 参考 | NA |
| 资本回报 参考 | NA |
| 持仓估值 参考 | NA |
| 风险溢价 参考 | NA |
| 市场估值 参考 | NA |
| 时机 30% | 0.7 |
| 过去一年没有明确趋势。股价远低于52周高点。 参考 | |
| 上升趋势:股价位于均线之上,均线向上。股价接近均线。 参考 | |
| 来自我们对走势图的 AI 技术分析。 参考 | NA |
| K线形态 参考 | NA |
| 市场情绪 20% | 0.0 |
| 近期没有目标价,因此依据目标价的调整方向。 参考 | |
| 持仓情绪 参考 | NA |
| 新闻情绪 参考 | NA |
| 聪明钱 20% | 3.2 |
| 机构在最新13F申报中净+15.00%的股份:90家增持,65家减持(截至30 Sep 2026的季度)。 参考 | |
| 空头持仓从31 Aug到30 Oct 2026变化+12.9%,回补天数8.8天(FINRA)。 参考 | |
| 内部交易活动 参考 | NA |
| 市场和行业状况不佳。 | |
| 市场环境偏谨慎。 参考 | |
| 行业表现落后大市。 | |
| 各支柱方向一致,评分因此加强。 | |
| 不计入评分 | |
| 每股盈利逐年上升。近年曾亏损。 参考 | |
| 高于中期趋势线。 参考 | |
| 股价接近其52周平均水平。5年来上涨。 参考 | |
| 短、中、长期趋势均向上。短期动能减弱。 参考 | |
| 股价接近支撑位。支撑与阻力水平趋降。 参考 | |
| 最终评分 | 0.91 |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 看涨 |
| Biotechnology (全球的) | 混合的 | 看涨 | |
| 股票 | Maze Therapeutics, Inc. | 混合的 | 看涨 |
相关股票
| 股票 | 市值 | DY | P/E(TTM) | P/B | 评分 |
|---|---|---|---|---|---|
| MAZE | 2 B | - | - | 4.13 | 0.9 |
| PBLS | 3 B | - | - | 3.38 | 0.8 |
| LEGN | 3 B | - | - | 2.59 | -1.6 |
| PVLA | 2 B | - | - | 10.82 | 0.9 |
| IMCR | 1 B | - | - | 3.24 | -0.2 |
| GPCR | 1 B | - | - | 1.01 | -0.8 |
|
Maze Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small-molecule precision medicines for patients living with renal, cardiovascular and related metabolic, or CVRM, diseases, including obesity. The company is advancing a pipeline using its Compass platform, which allows the company to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process it refers to as variant functionalization. It is currently advancing two programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for chronic kidney disease, or CKD. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 内部持股比例 | 1.55% |
| 机构持股比例 | 111.81% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Trv Gp Iv, Llc | 30 Jun 2026 | 4,473,958 |
该时间范围内无数据。
机构
机构持股比例: 119.75%
| 持仓变动 | 机构数 | 股数 |
|---|---|---|
| 增持 | 90 | 10,413,211 |
| 减持 | 65 | 4,730,262 |
| 新建仓 | 23 | 4,423,613 |
| 清仓 | 24 | 1,859,070 |
来源:经Nasdaq的SEC 13F申报,最新申报截至30 Sep 2026。申报在每季结束后45天内陆续提交。
空头持仓
| 结算日 | 股数 | 回补天数 |
|---|---|---|
| 30 Oct 2026 | 6,684,604 | 8.8 |
| 15 Oct 2026 | 7,527,939 | 10.1 |
| 30 Sep 2026 | 6,565,330 | 6.1 |
| 15 Sep 2026 | 5,678,289 | 10.4 |
| 31 Aug 2026 | 5,918,321 | 16.0 |
| 14 Aug 2026 | 5,988,933 | 16.2 |
来源:经Nasdaq的FINRA空头持仓数据,每月公布两次。
| 日期 | 类型 | 细节 |
|---|---|---|
| 09 Nov 2026 | Yahoo Finance |
Maze Therapeutics Reports Third Quarter 2026 Financial Results and Recent Highlights
Enrollment completed in Phase 2 HORIZON trial of MZE829; data from all three cohorts expected in early 2027 Enrollment ongoing in Phase 2 CIPheR trial of MZE782 in PKU; topline data expected in 2027 Phase 2 trial of MZE782 in CKD on track for H1 2027 initiation Strong balance sheet with $477… |
| 04 Nov 2026 | Yahoo Finance |
Wall Street Analysts Predict a 93.92% Upside in Maze Therapeutics, Inc. (MAZE): Here's What You Should Know
The average of price targets set by Wall Street analysts indicates a potential upside of 93.9% in Maze Therapeutics, Inc. (MAZE). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. |
| 03 Nov 2026 | Yahoo Finance |
Maze Therapeutics to Participate in Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with kidney and metabolic diseases, today announced that Jason Coloma, Ph.D., chief executive… |
| 19 Oct 2026 | Yahoo Finance |
What Makes Maze Therapeutics, Inc. (MAZE) a New Buy Stock
Maze Therapeutics, Inc. (MAZE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. |
| 19 Oct 2026 | Yahoo Finance |
Intel upgraded, PayPal downgraded: Wall Street's top analyst calls
Intel upgraded, PayPal downgraded: Wall Street's top analyst calls… |
| 19 Oct 2026 | Yahoo Finance |
How Much Upside is Left in Maze Therapeutics, Inc. (MAZE)? Wall Street Analysts Think 123.39%
The average of price targets set by Wall Street analysts indicates a potential upside of 123.4% in Maze Therapeutics, Inc. (MAZE). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the… |
| 13 Oct 2026 | Yahoo Finance |
Pompe Disease Market Set for Expansion During the Forecast Period (2026-2036) as Growth is Fueled by Next-Generation ERTs, Newborn Screening, and Pipeline Innovation | DelveInsight
Recently published Pompe Disease Market Insights report includes a comprehensive understanding of current treatment practices, Pompe disease emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United… |
| 06 Oct 2026 | Yahoo Finance |
Maze Therapeutics to Present Data from MZE829 and MZE782 Programs at ASN Kidney Week 2026
Oral presentation will highlight previously reported Phase 2 HORIZON data for MZE829 in patients with APOL1-mediated kidney disease Two poster presentations will highlight preclinical research supporting the therapeutic potential of SLC6A19 inhibition in chronic kidney disease SOUTH SAN FRANCISCO… |
| 05 Oct 2026 | Yahoo Finance |
3 Small-Cap Stocks With Catalysts That Could Put Them in the Spotlight
Small-cap stocks Ascentage Pharma, Maze Therapeutics, and Pagaya Technologies show improving fundamentals, strong cash positions, and bullish analyst ratings amid shifting investor interest. |
| 28 Sep 2026 | Yahoo Finance |
Could Vertex Pharmaceuticals (VRTX)’s Kidney Breakthrough Unlock a New Opportunity for Maze Therapeutics (MAZE)?
On September 22, Truist analyst Danielle Brill identified a “significant positive readthrough” for Maze Therapeutics, Inc. (NASDAQ:MAZE) following positive Phase 2 topline data from Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). The data validates APOL1 inhibition in classic APOL1-mediated… |
| 25 Sep 2026 | Yahoo Finance |
Maze Therapeutics (MAZE) Shares Moved, So What Is Driving Attention Now?
Fresh Coverage Puts Maze Therapeutics in Focus Maze Therapeutics (MAZE) moved higher in pre-market trading on 23 September after CIBC began covering the clinical-stage kidney and metabolic disease specialist, with the share reaction unfolding alongside new kidney data from Vertex Pharmaceuticals.… |
| 23 Sep 2026 | Yahoo Finance |
Maze Therapeutics Shares Rise 2.9% After CIBC Initiates Coverage
Maze Therapeutics (NASDAQ:MAZE) shares rose 2. 9% in pre-market trading after CIBC initiated coverage of the clinical-stage biopharmaceutical company with an Outperformer rating and a $50 price target. |
| 22 Sep 2026 | Yahoo Finance |
The Surprise That Sent Vertex — And Its Chief Rival — Soaring
Vertex stock popped Tuesday — while shares of rival Maze Therapeutics skyrocketed — on a surprise expansion for their kidney disease drugs. |
| 22 Sep 2026 | Yahoo Finance |
Twin Moves: VRTX Rises On Kidney Disease Trial Results, MAZE Rallies Harder
Vertex on Tuesday announced results from the mid-stage trial of its experimental pill, inaxaplin, in two groups of patients with APOL1-mediated kidney disease. |
| 22 Sep 2026 | Yahoo Finance |
Vertex’s Kidney Drug Success Sparks a 22% Surge for This Rival Biotech
Maze Therapeutics stock jumped after Vertex Pharmaceuticals reported positive results for inaxaplin, boosting confidence in a rival treatment from Maze. |
| 15 Sep 2026 | Yahoo Finance |
SCYNEXIS Appoints Todd Minga, M.D., as Senior Vice President, Research & Development
Experienced biopharmaceutical and nephrology leader joins SCYNEXIS to advance its rare disease development programsJERSEY CITY, N.J., Sept. 15, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX) (the Company or SCYNEXIS), a clinical-stage biotechnology company dedicated to advancing innovative… |
| 11 Sep 2026 | Yahoo Finance |
Maze Therapeutics Chief Medical Officer Dumps Entire Direct Stake in the Company for $255,000
The executive liquidated his entire direct holdings as the stock plunged about 50% from its 52-week high. |
| 02 Sep 2026 | Yahoo Finance |
Maze Therapeutics to Participate in Three Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with kidney and metabolic diseases, today announced that company management will participate… |
| 显示更多 | ||
近期信号 K线形态与EMA交叉
技术形态 中期
AI 技术分析
投资组合